Back to top
more

Regeneron Pharmaceuticals (REGN)

(Delayed Data from NSDQ)

$1,000.79 USD

1,000.79
439,734

-5.08 (-0.51%)

Updated Jun 6, 2024 04:00 PM ET

After-Market: $1,001.51 +0.72 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (86 out of 248)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Sanofi (SNY) Q1 Earnings Top, Sales Rise Y/Y, Shares Up

Sanofi (SNY) reported first-quarter 2017 earnings of 75 cents per American depositary share, which beat the Zacks Consensus Estimate of 73 cents by 2.7%.

    Amgen (AMGN) Q1 Earnings Top, Sales Miss, Shares Decline

    Biotech major Amgen Inc. (AMGN) reported first-quarter 2017 earnings of $3.15 per share, beating the Zacks Consensus Estimate of $3.00 by 5% .

      Arpita Dutt headshot

      Biotech Stock Roundup: Biogen Gains on Strong Q1, NASH Data on Gilead Drug

      Focus this week remained on Biogen's (BIIB) first quarter results which surpassed expectations.

        5 Reasons Why Sanofi (SNY) is a Good Stock to Buy Now

        Paris, France based Sanofi (SNY) is a global healthcare company possessing a diversified product portfolio.

          Arpita Dutt headshot

          Biotech Stock Roundup: Geron Gains on Interim Data, OncoMed Slumps on Pipeline Setback

          Key highlights this week included pipeline updates from companies like Geron (GERN) and OncoMed.

            Regeneron's Evinacumab Gets Breakthrough Therapy by FDA

            Regeneron Pharmaceuticals, Inc. (REGN) announced that the FDA has granted Breakthrough Therapy Designation status to ievinacumab for the treatment patients with Homozygous Familial Hypercholesterolemia.

              Arpita Dutt headshot

              4 FDA Decisions to Watch Out for in Apr 2017

              Companies like BioMarin (BMRN), Roche and Takeda among others have regulatory decisions scheduled for this month.

                Regeneron & Sanofi's Atopic Dermatitis Drug Gets FDA Nod

                Regeneron Pharmaceuticals, Inc. (REGN) and its partner Sanofi (SNY) announced that the FDA has approved the Dupixent (dupilumab) Injection, for the treatment of adults with moderate-to-severe atopic dermatitis (AD).

                  Arpita Dutt headshot

                  Biotech Stock Roundup: Regeneron, Tesaro Drugs Approved, Vertex Scores Big in Study

                  Key updates this week include the FDA approval of Tesaro's (TSRO) PARP inhibitor and Regeneron's eczema drug.

                    Arpita Dutt headshot

                    Biotech Stock Roundup: Amgen Down on Repatha Data, Nektar Surges on Pain Results

                    Biotech stocks were hit by the 2018 budget blueprint as well as news on companies like Amgen (AMGN) and Biogen.

                      Amgen (AMGN): Repatha Outcomes Data Disappoint, Shares Drop

                      Biotech major, Amgen, Inc. (AMGN) presented detailed results from the phase III cardiovascular outcomes study (FOURIER) on its PCSK9 inhibitor, Repatha.

                        What are Sanofi's (SNY) Strengths and Challenges in 2017?

                        We issued an updated research report on Sanofi (SNY) on Mar 16, 2017.

                          Arpita Dutt headshot

                          Biotech Stock Roundup: Amgen's Data on Repatha, Catalyst Soars on Firdapse Data

                          The biotech sector reacted favorably to President Donald Trump's pick for the top post in the FDA.

                            Amgen's Repatha Meets Primary Endpoint in Phase III Study

                            Amgen, Inc. (AMGN) announced positive data from a phase III study evaluating Repatha in patients who were receiving apheresis to help control their low-density lipoprotein cholesterol (LDL-C).

                              Why Amgen (AMGN) Stock Rallied After Q4 Earnings Release?

                              Biotech major, Amgen, Inc.'s (AMGN) shares have risen 12.1% since it reported better-than-expected fourth quarter results on Feb 2.

                                Sweta Killa headshot

                                A Trip to 8-Year Bull Run: What's Up, What's Down

                                While all the three major indices more than tripled scaling multiple highs in recent months, Nasdaq has won the maximum in the eight-year bull run.

                                  Arpita Dutt headshot

                                  5 FDA Decisions to Watch Out for in Mar 2017

                                  Companies like Merck (MRK) are awaiting key FDA decisions this month.

                                    Ophthotech (OPHT) Q4 Loss Wider than Expected, Sales Miss

                                    Ophthotech Corporation (OPHT) reported fourth-quarter 2016 loss of $1.86 per share, wider than both the Zacks Consensus Estimate of a loss of $1.64 and the year-ago loss of $1.02.

                                      Adverum (ADVM) to Post Q4 Earnings: What's in the Cards?

                                      Adverum Biotechnologies, Inc (ADVM) is expected to report fourth-quarter 2016 results on Mar 2.

                                        Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More

                                        The Q4 earnings season is on its last legs as results from 358 S&P 500 members or 71.6% of the index's total membership is already out.

                                          Amgen Looking to Broaden Leukemia Drug Blincyto's Label

                                          Biotech major Amgen Inc. (AMGN) announced that it has submitted a supplemental biologics license application (sBLA) to the FDA for its leukemia immunotherapy Blincyto.

                                            Arpita Dutt headshot

                                            Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data

                                            Gilead (GILD) presented promising HIV data while Regeneron's PCSK9 inhibitor will remain on the market during the appeals process.

                                              Regeneron (REGN) Misses on Q4 Earnings & Sales, View Bleak

                                              Regeneron Pharmaceuticals, Inc. (REGN) reported disappointing results for the fourth quarter of 2016. The outlook for 2017 did not give investors anything to cheer for either.

                                                Ekta Bagri headshot

                                                Regeneron (REGN) Q4 Earnings Misses Estimates

                                                Regeneron???s fourth-quarter 2016 earnings missed expectations

                                                  Sanofi (SNY) Q4 Earnings In Line; Can Sell Praulent for Now

                                                  Sanofi (SNY) reported fourth-quarter 2016 earnings of 67 cents per American depositary share, which was in line with the Zacks Consensus Estimate.